肝小静脉闭塞病新药——去纤苷

What is the new drug for hepatic veno-occlusive disease - defibrotide (defiteli)? In recent years, there have been an increasing number of patients with hepatic veno-occlusive disease. Defibrotide (defiteli) is a very effective drug for preventing and treating hepatic veno-occlusive disease (HVOD) after hematopoietic stem cell transplantation (HSCT). It is also called defiteli. It was developed by Jazz Company and was approved for marketing in the EU in October 2013. HVOD is one of the serious complications of HSCT. The mortality rate of patients with severe HVOD can be as high as 100%, and the risk of death is extremely high. Defibrotide (defiteli) is currently recognized as the most promising new drug for the treatment of HVOD.

The effectiveness of defibrotide (defiteli) in the treatment of HVOD patients was explored in a study, in which 19 patients with sHVOD were enrolled. Give defibrotide treatment, intravenous infusion, 5~60 mg/kg per day, the median use time is 15 days (2-61 days). The results showed that 42% of the patients achieved complete remission (CR), and the overall survival rate 100 days after transplantation (OS) reached 32%. The patients also tolerated defibrotide (defiteli) relatively well. In addition, many trials have confirmed that defibrotide (sodium defibrotide) is safe and effective in the treatment of hepatic veno-occlusive disease (HVOD).

Defibrotide (defiteli) has also been granted "orphan drug" status by the FDA. It can be used not only by adults, but also by children. In order to exert the effect of defibrotide in the treatment of hepatic venule occlusion, patients need to take the medication correctly. The recommended dose of defibrotide (defiteli) is 6.25 mg/kg given as a 2-hour intravenous infusion every 6 hours based on body weight.

The above is the drug introduction of defiteli provided by our Medical Companion Travel Service. If the patient has any other questions, please consult the Medical Companion Travel Service.